A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Conditions

• Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• TORL-5-700 — DRUG
  Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks
• TORL-5-700 at MTD/RP2D — DRUG
  Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks
• TORL-5-700 at MTD/RP2D in combination with another agent — DRUG
  Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent

Study Details

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Key Dates

Start date

Mar 31, 2026

Status verified

Jun 2026

Primary completion

Mar 31, 2029

Completion

Sep 30, 2029

Study Design

Enrollment

155 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Part 1: Monotherapy Dose Escalation
  TORL-5-700 Administered once every three weeks
• Experimental: Part 2: Monotherapy Expansion
  TORL-5-700 at MTD/RP2D Administered once every three weeks
• Experimental: Part 3: Combination Evaluation
  TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent

Primary Outcome Measure

Evaluate the safety of TORL-5-700 as a monotherapy [ Time Frame: though study completion, an average of 2.5 years ]

Central Contacts

• Timothy Welliver, M.D.
  (310) 598-5969
  [email protected]

Locations (3)

Find similar trials in Santa Monica, CA